This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $187,500 to St. John's University in New York to investigate the role of lipocalin prostaglandin D2 synthase (L-PGDS) and its metabolite PGD2 in non-alcoholic fatty liver disease (NAFLD). The research aims to elucidate the effect of insulin signaling on L-PGDS expression and function, examine the impact of L-PGDS on glucose and lipid metabolism, and determine the role of PGD2 receptor modulators in NAFLD using in vitro and in vivo models. This research is expected to shed new light on the involvement of L-PGDS in liver physiology and its link to insulin resistance and obesity, potentially leading to the identification of novel therapeutic targets for NAFLD. The award period is from Aug 10, 2024 to Jun 30, 2028.
Generated 1/28/25, 9:30 AM